rs764603059
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PP5BS2_Supporting
The NM_174936.4(PCSK9):c.103G>T(p.Asp35Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000572 in 1,573,692 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 34)
Exomes 𝑓: 0.0000056 ( 0 hom. )
Consequence
PCSK9
NM_174936.4 missense
NM_174936.4 missense
Scores
8
11
Clinical Significance
Conservation
PhyloP100: 0.883
Genes affected
PCSK9 (HGNC:20001): (proprotein convertase subtilisin/kexin type 9) This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PP5
Variant 1-55039940-G-T is Pathogenic according to our data. Variant chr1-55039940-G-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 375848.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=3, Uncertain_significance=3, Pathogenic=2}.
BS2
High AC in GnomAdExome4 at 8 AD gene. Variant has AC lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCSK9 | NM_174936.4 | c.103G>T | p.Asp35Tyr | missense_variant | 1/12 | ENST00000302118.5 | NP_777596.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCSK9 | ENST00000302118.5 | c.103G>T | p.Asp35Tyr | missense_variant | 1/12 | 1 | NM_174936.4 | ENSP00000303208 | P2 | |
PCSK9 | ENST00000710286.1 | c.460G>T | p.Asp154Tyr | missense_variant | 1/12 | ENSP00000518176 | A2 | |||
PCSK9 | ENST00000673913.2 | c.103G>T | p.Asp35Tyr | missense_variant, NMD_transcript_variant | 1/12 | ENSP00000501161 | ||||
PCSK9 | ENST00000673726.1 | c.103G>T | p.Asp35Tyr | missense_variant, NMD_transcript_variant | 1/6 | ENSP00000501004 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152284Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
1
AN:
152284
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000108 AC: 2AN: 185654Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 99494
GnomAD3 exomes
AF:
AC:
2
AN:
185654
Hom.:
AF XY:
AC XY:
0
AN XY:
99494
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000563 AC: 8AN: 1421408Hom.: 0 Cov.: 31 AF XY: 0.00000569 AC XY: 4AN XY: 703200
GnomAD4 exome
AF:
AC:
8
AN:
1421408
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
703200
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152284Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 74400
GnomAD4 genome
AF:
AC:
1
AN:
152284
Hom.:
Cov.:
34
AF XY:
AC XY:
0
AN XY:
74400
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:5Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Hypercholesterolemia, autosomal dominant, 3 Pathogenic:3Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of molecular diagnosis of dyslipidemias, Università egli studi di Napoli Federico II | May 24, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 18, 2023 | This missense variant replaces aspartic acid with tyrosine at codon 35 of the PCSK9 protein. Computational prediction tools indicate that this variant has a neutral impact on protein structure and function. A functional study has shown that the mutant protein causes slightly higher reduction in LDLR on cell surface by creating a novel Tyr-sulfation site that may enhance the intracellular activity of PCSK9 (PMID: 22683120). Another high-throughput functional study using transfected HEK293 cells has shown that this variant does not impact PCSK9 processing (PMID: 29259136). This variant has been reported in two related individuals affected with familial hypercholesterolemia in one family (PMID: 22683120), and additionally in two unrelated individuals affected with familial hypercholesterolemia (PMID: 29127338; ClinVar SCV002246507.1). It has also been reported in one individual affected with hyperlipidemia (PMID: 33303402). This variant has been identified in 2/185654 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 05, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 35 of the PCSK9 protein (p.Asp35Tyr). This variant is present in population databases (rs764603059, gnomAD 0.004%). This missense change has been observed in individuals with clinical features of familial hypercholesterolemia (PMID: 22683120, 29127338; Invitae). ClinVar contains an entry for this variant (Variation ID: 375848). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PCSK9 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PCSK9 function (PMID: 22683120). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix | Dec 16, 2016 | subject mutated among 2600 FH index cases screened = 1, family member = 1 / functionnal testing (PMID:22683120) / Software predictions: Conflicting - |
PCSK9-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 25, 2023 | The PCSK9 c.103G>T variant is predicted to result in the amino acid substitution p.Asp35Tyr. This variant has been reported in multiple individuals with hypercholesterolemia (Abifadel et al. 2012. PubMed ID: 22683120; Di Taranto et al. 2017. PubMed ID: 29127338; Chorba et al. 2017. PubMed ID: 29259136. Table S2). Functional study showed that this variant alters PCSK9 function (Abifadel et al. 2012. PubMed ID: 22683120). This variant is reported in 0.0041% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-55505613-G-T). This variant is interpreted as likely pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 05, 2023 | Published functional studies demonstrate a damaging gain-of-function effect (Abifadel et al., 2012); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31589614, 33303402, 29127338, 29038906, 22683120) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 27, 2019 | The p.D35Y variant (also known as c.103G>T), located in coding exon 1 of the PCSK9 gene, results from a G to T substitution at nucleotide position 103. The aspartic acid at codon 35 is replaced by tyrosine, an amino acid with highly dissimilar properties. This alteration has been reported in two related individuals with hypercholesterolemia (Abifadel M et al. Atherosclerosis, 2012 Aug;223:394-400). Functional studies suggest that this alteration creates a new tyrosine sulfation site similar to the nearby Y38 sulfation site, but the physiological relevance of this is unclear (Abifadel M et al. Atherosclerosis, 2012 Aug;223:394-400). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Familial hypercholesterolemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 29, 2023 | This missense variant replaces aspartic acid with tyrosine at codon 35 of the PCSK9 protein. Computational prediction tools indicate that this variant has a neutral impact on protein structure and function. A functional study has shown that the mutant protein causes slightly higher reduction in LDLR on cell surface by creating a novel Tyr-sulfation site that may enhance the intracellular activity of PCSK9 (PMID: 22683120). Another high-throughput functional study using transfected HEK293 cells has shown that this variant does not impact PCSK9 processing (PMID: 29259136). This variant has been reported in two related individuals affected with familial hypercholesterolemia in one family (PMID: 22683120), and additionally in two unrelated individuals affected with familial hypercholesterolemia (PMID: 29127338; ClinVar SCV002246507.1). It has also been reported in one individual affected with hyperlipidemia (PMID: 33303402). This variant has been identified in 2/185654 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Benign
T
M_CAP
Uncertain
D
MetaRNN
Uncertain
T
MetaSVM
Benign
T
MutationAssessor
Benign
L
MutationTaster
Benign
N;N
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Benign
T
Polyphen
B
Vest4
MutPred
Gain of phosphorylation at D35 (P = 0.0099);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at